{
    "clinical_study": {
        "@rank": "161439", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D analogue", 
                "arm_group_type": "Experimental", 
                "description": "1-\u03b1 hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Corn oil pearl Capsules 1 gram"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this double blind clinical trial study is to investigate whether alphacalcidol\n      treatment in obese subjects can affect the resting metabolic rate. Moreover, the\n      investigators will evaluate the pathways of Nesfatin-1, Peroxisome proliferator-activated\n      receptor gamma (PPAR\u03b3) and eroxisome proliferator-activated receptor- coactivator-1 \u03b1\n      (PGC1\u03b1) protein which may lead to change in metabic rate following treatment with either\n      alphacalcidol or placebo."
        }, 
        "brief_title": "Assessment Vitamin D Analogues Intake Pathways on the Proteins Which Involved in Metabolic Rate in Obese Subjects", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Age 22-52 years Body mass index equal or more than 30\n\n        Exclusion Criteria:\n\n        Acute or chronic inflammatory disease History of hypertension Alcohol or drug abuse\n        History of any condition affecting inflammatory markers Thyroid diseases Malignancies\n        Current smoking Diabetes mellitus Sustained hypertension Heart failure Acute or chronic\n        infections Hepatic or renal diseases Use of PPAR\u03b3 agonist drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "52 Years", 
            "minimum_age": "22 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01894295", 
            "org_study_id": "91-03-27-18831"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "corn oil capsule"
            }, 
            {
                "arm_group_label": "Vitamin D analogue", 
                "description": "1-\u03b1 hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks", 
                "intervention_name": "Vitamin D analogue", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "1-\u03b1 hydroxyvitamin D3"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Ergocalciferols", 
                "Hydroxycholecalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vitamin D analogues", 
            "Resting Metabolic rate", 
            "obesity"
        ], 
        "lastchanged_date": "July 9, 2013", 
        "location": {
            "contact": {
                "email": "jalalimahmoud@hotmail.com", 
                "last_name": "Mahmoud Jalali, PhD"
            }, 
            "contact_backup": {
                "email": "mina_mirzaei101@yahoo.com", 
                "last_name": "Khadijeh Mirzaei, MS"
            }, 
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "TehranUMS"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "description": "Measurement by ELISA kit", 
            "measure": "Change of ACS and FASN Enzymes", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline to 8 weeks"
        }, 
        "overall_contact": {
            "email": "jalalimahmoud@hotmail.com", 
            "last_name": "Mahmoud Jalali, Phd", 
            "phone": "+982188954911"
        }, 
        "overall_contact_backup": {
            "email": "mina_mirzaei101@yahoo.com", 
            "last_name": "Khadijeh Mirzaei, MS", 
            "phone": "+989124379670"
        }, 
        "overall_official": [
            {
                "affiliation": "Tehran University of Medical Sciences", 
                "last_name": "Mahmoud Jalali, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Tehran University of Medical Sciences", 
                "last_name": "Khadijeh Mirzaei, MS", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Iran: Ethics Committee"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Measurement by indirect calorimetry.", 
            "measure": "Resting Metabolic Rate", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01894295"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measurement by ELISA kit", 
            "measure": "Changes of Nesfatin-1, PPAR\u03b3 and PGC1\u03b1 protein levels", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline to 8 weeks"
        }, 
        "source": "Tehran University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tehran University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}